Pancreatic cancer

Research from the International Cancer Benchmarking Partnership has found a link between cancer policy consistency over time and survival for six cancer types

Around 8 in 10 pancreatic cancer cases are currently diagnosed late in England and Wales.

Scientists from the University of Glasgow are developing new ways to predict who will respond to drugs targeting damaged DNA in pancreatic cancer. 

Researchers in Cambridge have pioneered the development of an innovative affinity maturation technique to generate high-affinity antibody against Arginase 2.

Our scientists are using hydrogels to understand more about how pancreatic cancer cells spread.

We speak to our scientists who are developing urine tests that aim to detect bladder and pancreatic cancer earlier.

Dr Catherine Hogan has been funded by Cancer Research UK’s Early Detection Committee to understand pancreatic cancer cells and develop new diagnostic tools.

US researchers have found a link between the makeup of bacteria in the tumours of people with pancreatic cancer and how long they live.

A drug that’s designed to target weaknesses inside cancer cells can hold some advanced pancreatic cancers at bay for a short time after chemotherapy.

A dual kinase inhibitor is entering a clinical trial for advanced pancreatic cancer in combination with gemcitabine.